Case report: Streptomycin combined with dacronin in painless magnifying endoscopy

Abstract

Rationale: To analyze the effect of streptomyces protease combined with dyclonine in painless magnifying endoscopy. Patient concerns: A total of 100 patients who underwent magnification endoscopy in our hospital from January 2021 to June 2022 were retrospectively analyzed. Diagnoses: The diagnoses were made by painless magnifying endoscopy and narrow-band imaging combined with pathological findings. Interventions: The patients were divided into the observation group and control group, the observation group was streptomyces protease combined with dyclonine group, and the control group was dyclonine group, 50 cases in each group. The visibility score under gastroscopy was compared between the 2 groups, and the morphological classification of gastric pit and collecting veins was observed. The detection rates of small lesions and early cancer were compared between the 2 groups. The examination time and adverse reactions were compared between the 2 groups. Outcomes: Compared with the control group, the streptomyces protease combined with dyclonine group had better clear visibility and a higher detection rate of small lesions, but there was no significant difference in early cancer detection rate between the 2 groups. The examination time of streptomyces protease combined with dyclonine group was relatively prolonged, but there was no significant difference in the incidence of adverse reactions between the 2 groups. Lessons: Streptomyces protease combined with dyclonine plays a certain role in painless magnifying gastroscopy, which can improve the visibility of gastroscopy, improve the detection rate of small lesions, help to find gastric dysplasia and early gastric cancer diagnosis, and does not increase the incidence of adverse reactions.